Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.
Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.
Address: Top Floor, 111 Rathmines Road Lr, Dublin 6
Tel: 353 (01) 441 0024
GreenCross Publishing is owned by Graham Cooke.
Licences have been issued for treatment of six individual patients via the Ministerial licence route. Valid applications received are assessed “without delay”, according to the Department.
“The legal basis for the Ministerial licence for medical cannabis in exceptional circumstances is the Misuse of Drugs Acts 1977-2017. The Medical Cannabis Access Programme, once operational, will operate as a separate scheme for the facilitation of access to medical cannabis for certain specified medical conditions in certain circumstances.”
Clinical guidelines for the access programme have been finalised and will be published on the Department’s website “shortly”.
Dr Máirín Ryan, HIQA’s Deputy Chief Executive and Director of Health Technology Assessment, was appointed as chair of an expert reference group tasked with developing operational, clinical and practice guidelines for the access programme for medical cannabis in Ireland.
“The clinical guidelines have now been finalised and will be published on the Department’s website shortly,” said the Department spokesperson. “The guidelines are intended for use by healthcare professionals using medical cannabis-based products for the treatment of patients under their care. They provide detailed guidance under the headings: aims; context and scope; guidelines for treatment; contraindications and precautions and ongoing monitoring.
“The expert reference group has met on seven occasions and has also carried out extensive targeted consultations.”
The HSE has been requested to establish and maintain a patient register to facilitate the access programme. Work is continuing in relation to sourcing suitable quality-controlled, affordable, cannabis-based products for Irish patients.
Drafting of secondary legislation to underpin the access programme continues and will be finalised “once appropriate cannabis product supplies have been established”, according to the Department.
In February 2017, Minister for Health Simon Harris published <em>Cannabis for Medical Use – A Scientific Review </em>which was undertaken by the Health Products Regulatory Authority (HPRA).
On foot of this report, the Minister decided to establish an access programme for medical cannabis-based treatments for spasticity associated with multiple sclerosis; intractable nausea and vomiting associated with chemotherapy; and severe, refractory epilepsy that has failed to respond to standard anticonvulsant medications.
Patients accessing medical cannabis through the access programme must be under the shared care of their GP and medical consultant to monitor progress.
The IMO has commenced a ballot of NCHDs on industrial action up to and including strike...
The National Office of Clinical Audit (NOCA) has announced the publication of the National Paediatric Diabetes...
The ICGP is examining alternative pathways for entry into general practice training as part of efforts...
In December, the HSE released part of an external review into the case of 'Brandon', a...
The evidence on doctor burnout “should scare us and concern us”, the Director of the RCSI...
A review of public health governance structures and addressing “longstanding” IT infrastructure...
Leave a Reply
You must be logged in to post a comment.